346 related articles for article (PubMed ID: 16357129)
21. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
22. The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.
Voduc D; Nielsen TO; Cheang MC; Foulkes WD
Hum Pathol; 2008 Oct; 39(10):1431-7. PubMed ID: 18620730
[TBL] [Abstract][Full Text] [Related]
23. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer.
Li X; Cao X; Li X; Zhang W; Feng Y
Cancer Sci; 2007 Oct; 98(10):1592-6. PubMed ID: 17651454
[TBL] [Abstract][Full Text] [Related]
24. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
25. GATA binding protein 3 is down-regulated in bladder cancer yet strong expression is an independent predictor of poor prognosis in invasive tumor.
Miyamoto H; Izumi K; Yao JL; Li Y; Yang Q; McMahon LA; Gonzalez-Roibon N; Hicks DG; Tacha D; Netto GJ
Hum Pathol; 2012 Nov; 43(11):2033-40. PubMed ID: 22607700
[TBL] [Abstract][Full Text] [Related]
26. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
27. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
28. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
[TBL] [Abstract][Full Text] [Related]
29. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of osteopontin in patients with triple-negative breast cancer.
Wang X; Chao L; Ma G; Chen L; Tian B; Zang Y; Sun J
Eur J Clin Invest; 2008 Jun; 38(6):438-46. PubMed ID: 18452545
[TBL] [Abstract][Full Text] [Related]
31. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast.
Kleer CG; Griffith KA; Sabel MS; Gallagher G; van Golen KL; Wu ZF; Merajver SD
Breast Cancer Res Treat; 2005 Sep; 93(2):101-10. PubMed ID: 16187229
[TBL] [Abstract][Full Text] [Related]
32. Is triple negative a prognostic factor in breast cancer?
Nishimura R; Arima N
Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
34. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
[TBL] [Abstract][Full Text] [Related]
35. Population-based molecular prognosis of breast cancer by transcriptional profiling.
Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
[TBL] [Abstract][Full Text] [Related]
36. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
37. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy.
Yang Q; Moran MS; Haffty BG
Breast Cancer Res Treat; 2009 May; 115(2):343-8. PubMed ID: 18516673
[TBL] [Abstract][Full Text] [Related]
38. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer.
Linder N; Lundin J; Isola J; Lundin M; Raivio KO; Joensuu H
Clin Cancer Res; 2005 Jun; 11(12):4372-81. PubMed ID: 15958620
[TBL] [Abstract][Full Text] [Related]
39. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
Rody A; Karn T; Ruckhäberle E; Müller V; Gehrmann M; Solbach C; Ahr A; Gätje R; Holtrich U; Kaufmann M
Breast Cancer Res Treat; 2009 Feb; 113(3):457-66. PubMed ID: 18340528
[TBL] [Abstract][Full Text] [Related]
40. Expression of neuronal protein synuclein gamma gene as a novel marker for breast cancer prognosis.
Wu K; Quan Z; Weng Z; Li F; Zhang Y; Yao X; Chen Y; Budman D; Goldberg ID; Shi YE
Breast Cancer Res Treat; 2007 Mar; 101(3):259-67. PubMed ID: 16821081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
